1.Fridkin, SK, Steward, CD, Edwards, J, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999;29:245–252.
2.Archibald, L, Phillips, L, Monnet, D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211–215.
3. NNIS System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–485.
4.Bryce, EA, Smith, JA. Focused microbiological surveillance and gram-negative β-lactamase-mediated resistance in an intensive care unit. Infect Control Hosp Epidemiol 1995;16:331–334.
5.Livermore, DM, Yuan, M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp from intensive care units in Europe. J Antimicrob Chemother 1996;38:409–424.
6.Neuhauser, MM, Weinstein, RA, Rydman, R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885–888.
7.Hanberger, H, Garcia-Rodriguez, J-A, Gobernado, M, et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999;281:67–71.
8.Kollef, MH, Fraser, VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001;134:298–314.
9.Carmeli, Y, Troillet, N, Karchmer, AW, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127–1132.
10.Carlet, J, Ben Ali, A, Chalfine, A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004;17:309–316.
11.Lautenbach, E, Strom, BL, Nachamkin, I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004;38:655–662.
12. WHO Collaborating Centre for Drug Statistics Methodology Web site. Available at: http://www.whocc.no/atcddd/. Accessed January 18, 2007.
13.Garner, JS, Jarvis, WR, Emori, TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.
14.Papia, G, Louie, M, Traila, A, et al. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to hospital: is it cost-effective? Infect Control Hosp Epidemiol 1999;20:473–477.
15.Muto, CA, Jernigan, JA, Ostrowsky, BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362–386.
16.Clinical and Laboratory Standards Institute / NCCLS. Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. CLSI/NCCLS document M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
17.Cheong, H-J, Yoo, C-W, Sohn, J-W, et al. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 2001;33:48–53.
18.Gentry, C, Flournoy, DJ, Reinert, R. Analysis of antimicrobial resistance among gram-negative bacilli and antimicrobial use in intensive care unit patients for 5 years in a Veterans Affairs medical center. Am J Infect Control 2002;30:411–416.
19.Zervos, MJ, Hershberger, E, Nicolau, DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37:1643–1648.
20.MacDougall, C, Harpe, SE, Powell, JP, et al. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005;11:1197–1204.
21.Aubert, G, Carricajo, A, Vautrin, A-C, et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. / Hosp Infect 2005;59:83–89.
22.Polk, RE, Johnson, CK, McClish, D, et al. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004;39:497–503.
23.Paterson, DL, Mulazimoglu, L, Casellas, JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473–478.
24.Lautenbach, E, Fishman, NO, Bilker, WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:2469–2477.
25.Ray, GT, Baxter, R, DeLorenze, GN. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-non-susceptible Pseudomonas aeruginosa. Clin Infect Dis 2005;41:441–449.
26.Muder, RR, Brennen, C, Goetz, AM, et al. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother 1991;35:256–258.
27.Carmeli, Y, Troillet, N, Eliopoulos, GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379–1382.
28.Richard, P, Delangle, M-H, Merrien, D, et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 1994;19:54–59.
29.El Amari, EB, Chamot, E, Auckenthaler, R, et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001;33:1859–1864.
30.Harbarth, S, Harris, AD, Carmeli, Y, et al. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 2001;33:1462–1468.
31.Huotari, K, Tarkka, E, Valtonen, V, et al. Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis 2003;22:492–495.
32.Gilbert, DN, Kohlhepp, SJ, Slama, KA, et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 2001;45:883–892.
33.Ortiz, J, Vila, MC, Soriano, G, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999;29:1064–1069.
34.Lautenbach, E, Metlay, JP, Bilker, WB, et al. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005;41:923–929.